評論
打印
This better-safe-than-sorry approach has led to unnecessary treatment, which might now be avoided.
這種“保險總比遺憾好”的態度促成了諸多不必要的治療，如今或許都可以免去了。
An earlier arm of TAILORx showed that women with low risk of recurrence (scores below 10) might not need chemotherapy;
TAILORx的早期研究就表明，復發風險較低（得分低于10分）的患者或許并不需要化療；
now more than 60,000 women in the U.S. with intermediate risk scores up to 25 can be added to that group.
如今，6萬余名評估結果高達25分，面臨中等復發風險的患者也能被劃入這一行列了。
“Chemo is not killing any more cancer cells than are being killed by hormone therapy,” says Norton.
“化療殺死的癌細胞并不比激素療法殺死的癌細胞多，”諾頓說道。
“I don’t see chemo playing a role in this setting at all.”
“我并不覺得化療在這方面能發揮多大作用。”
This new treatment strategy applies mostly to women older than 50, who are usually past menopause,
這種新的治療方案主要適用于50歲以上，通常已經過了更年期的女性患者，
when levels of estrogen, which feeds breast tumors, start to drop.
因為這一年齡段的女性體內，乳腺腫瘤所依賴的雌激素水平已經開始下降了。
For younger women with intermediate risk scores (16 to 25),
但對于面臨中等風險（評估結果在16~25分之間）的年輕女性而言，
there may still be some benefit to relying on chemotherapy
化療或許仍有一定的好處，
since it may push them into early menopause and lower their exposure to estrogen.
因為化療可能會讓她們提前絕經，降低她們體內雌激素的水平。
THE RESULTS MAY HERALD a new era in which doctors make smarter decisions about how much is enough when treating certain cancers.
這一研究結果或許預示著一個新時代的到來——醫生們在治療某些癌癥時，對于多大強度才算足夠這一問題終于能做出更明智的決定了。
“This is the dawn of the de-escalation era,” says Hurvitz.
“這一發現堪稱拉開了降級時代的序幕，”赫維茲說。
“We need to move forward looking for ways to deescalate therapy
“針對那些既限制了患者的生活質量，還會給患者帶來潛在傷害的治療方案，
that is not just limiting quality of life but also potentially harming patients.”
我們有必要繼續尋找降低這類治療的強度的辦法。”
That streamlining can also contribute to cost savings.
提高治療效率也有助于節省成本。
The Oncotype DX test runs about $3,000 to $4,000 (covered by most insurers),
Oncotype DX檢測的費用為3000~4000美元(大多數保險公司都有覆蓋)，
but for tens of thousands of women it could potentially spare them from chemotherapy, which can cost, on average, $20,000.
但對成千上萬的女性患者而言，這一研究結果或許能幫她們免去均價高達2萬美元的化療。
Even apart from the financial benefit, for women like Lacetti, the findings provide welcome reassurance
即便不考慮經濟利益，對于拉凱蒂這樣的患者而言，此次的研究結果還是一劑令人欣慰的強心劑，
that they can avoid a dreaded part of cancer care that comes with serious side effects and long-term health consequences.
表明她們可以免去癌癥治療過程中十分可怕，可能伴隨嚴重的副作用以及長期的健康問題的一個環節。
“It’s wonderful,” she says.
“太好了，”她說。
“My sister had to quit her job to do chemo and stayed in the hospital for 11 months.
“當初，我姐姐為了化療把工作都辭了，還住了11個月的院。
I’m able to keep my job and spend more time with my family.
我不僅能繼續工作，還能有更多時間陪伴家人。
I’m glad they had this study, and I’m glad I was able to be a part of it.”
我很高興他們做了這項研究，也很高興能參與其中。”
